Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MiRNA-seq of CD4+ T cells transfected by ASO or CRO

ABSTRACT: During the activation of CD4+T cells, the pri-miRNAs translocated from cytoplasma into nucleus.However, the mechanism remains unkown. We found that pri-miR-31 interact with nucleolin through G-guadruplex struction in pri-miR-31. We then transfected ASO to destribute the interaction of nucleolin and G4 struction. miRNA-seq was performed in our study.

ORGANISM(S): Mus musculus

PROVIDER: GSE263730 | GEO | 2025/04/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RIP-seq reveals the interactome of nucleolin in activated CD4+ T cells

Project description:During the actiation of CD4+T cells, the pri-miRNAs translocated from cytoplasma into nucleus.However, the mechanism remains unkown. We found that pri-miR-31 interact with nucleolin through G-guadruplex struction in pri-miR-31. We then transfected ASO to destribute the interaction of nucleolin and G4 struction. In order to identify the interacting RNA, including miRNA precuser and mRNA, we performed the RIP-seq Immunoprecipited by anti-nucleolin and IgG.

2025-04-11 | GSE263822 | GEO

LC-MS to identy the interacting protein with pri-miR-31 in CD4+ T cells

Project description:This project was aimed to identify the proteomic of pri-miR-31 interacting in naïve and activated cd4+ T cells. Immunoprecipitates pulled down by pri-miR-31 were subjected to LC-MS. Our results reveal the interacting protein in different state of CD4+ T cells.

2024-06-24 | PXD038182 | Pride

mRNA expression profile in IL-4-treated macrophages transfected with miR-142-5p ASO or miR-130a-3p mimics

Project description:To identify target genes of miR-142-5p and miR-130a-3p that are involved in M2 polarization, we examined the mRNA expression profile changes after altering miR-142-5p or miR-130a-3p expression in IL-4-treated macrophages. Macrophages were transfected with control ASO, miR-142-5p ASO, control mimics or miR-130-3p mimics using lentiviral vectors. After 24 hr, the cells were treated with IL-4 for 24h.mRNA was purified from total RNA after removal of rRNA (mRNA-ONLY™ Eukaryotic mRNA Isolation Kit, Epicentre). Then, each sample was amplified and transcribed into fluorescent cRNA along the entire length of the transcripts without 3’ bias utilizing a random priming method. The labeled cRNAs were hybridized onto the Human RNA Array v2.0 (8 x 60K, Arraystar). After having washed the slides, the arrays were scanned by the Agilent Scanner G2505B.

2014-07-12 | E-GEOD-59347 | biostudies-arrayexpress

HF liver: Control vs. Plin2-ASO treated

Project description:Transcriptional profiling of mouse liver comparing control, scrambled-oligonucleotides (Cont)-treated mice with Perilipin 2-antisense oligonucleotides (Plin2-ASO)-treated mice. C57BL/6 mice on a high-fat diet were treated with oligonucleotides in vivo. The goal was to determine the effects of Plin2 down-regulation in the liver on global gene expression. Two-condition experiment, control oligonucleotides vs. Plin2-antisense oligonucleotides. Biological replicates: 4 control replicates, 4 Plin2-ASO replicates.

2012-12-05 | E-GEOD-37011 | biostudies-arrayexpress

RNA sequencing analysis of intracranial D425 xenografts treated with ASO-CTRL and ASO-lnc-HLX 2-7

Project description:To gain more insights into the functional significance of lnc-HLX-2-7, gene expression profiles were measured using D425 (sh-CTRL), D425 (sh-HLX) and intracranial D425 xenografts treated with ASO-CTRL and ASO-lnc-HLX 2-7 by RNA sequencing.

2023-11-01 | GSE188746 | GEO

Gene expression profiling of HCCLM3 cells: Control ASO vs SCARNA13 ASO

Project description:Gene expression profiling of HCCLM3 cells: Control ASO vs SCARNA13 ASO

| PRJNA491641 | ENA

polyA site sequencing (PAS-seq) analysis of Hela cells treated with NC ASO or snoRD50a ASOs

Project description:Our RNA-seq experiment (E-MTAB-5383) and subsequent in vitro analysis suggested that snoRD50a is a trans-acting RNA that can function in mRNA 3' processing. To test this hypothesis at transcriptomic level, we performed PAS-seq experiments to compare the polyA+ transcripts profile between negative control ASO (nc ASO) and snoRD50a ASO treated Hela cells, ASO (antisense oligonucletode) technique is a commonly used technique to deplete nuclear RNAs. snoRD50a ASO is used to deplete endogenous snoRD50a. See related experiments: E-MTAB-5383; E-MTAB-5384.

2017-05-31 | E-MTAB-5389 | biostudies-arrayexpress

RNA-seq analysis of HeLa cells following MYC inhibition with ASO

Project description:We performed RNA-seq on HeLa cells treated with MYCASO-3, a non-targeting ASO (NT-ASO), Lipofectamine alone, and untreated cells

2021-10-19 | GSE183535 | GEO

The transcriptome profile after antisense L1 ASO treatment [ssRNA-Seq]

Project description:We performed RNA-seq assay in Scramble ASO and antisense Mus1_L1 ASO treated AML12 cells to reveal the trscriptiome associated with MATR3 protein. The libraries were constructed by ribosome-depleted and strand-specific kits.

2023-06-28 | GSE228646 | GEO

A Biodistribution Study of OTV vs. ASO by Intravenous or Intrathecal Administration in Cynomolgus Monkeys

Project description:The objective of this study is to evaluate ASO biodistribution and pharmacodynamic response following intravenous delivery of conjugated OTV, which utilizes transferrin-receptor binding to deliver ASO, vs. intrathecal delivery of naked ASO in cynomolgus monkeys, the current gold standard for ASO delivery. Three groups were included for comparison: 1) Negative control cohort = Four biweekly intravenous doses of saline (n=3); 2) IT cohort = Single intrathecal dose of 4mg MALAT1 ASO (n=3); 3)  OTV multi dose cohort = Four biweekly intravenous doses of 30mpk OTV:MALAT1 (n=3). Tissues were collected two weeks after the final dose to allow sufficient time for target knockdown. Brain, spinal cord, and peripheral tissues were dissected and frozen for molecular analysis. Compared to an intrathecal injection of ASO, systemic administration of OTV resulted in significantly more homogenous biodistribution of ASO in the central nervous system as measured by a probe-based hybridization assay as well as staining with an anti-ASO antibody. One potential consequence of heterogeneous ASO distribution is heterogeneous target knockdown throughout the CNS. We observed more consistent target knockdown throughout the cortex, subcortical areas, and spinal cord of monkeys dosed peripherally with OTV. By contrast, monkeys dosed intrathecally with naked ASO showed much more knockdown in the spinal cord compared to the brian, consistent with ASO distribution.

2024-02-12 | GSE208114 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data